Skip to main content

Table 1 Demographics and clinical characteristics of study cohort at baseline

From: One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study

 

Oxygen only

(N = 61)

CPAP

(N = 136)

IMV

(N = 90)

p

Age (years), median [Q1–Q3]

60.7 [53.7, 71.4]

60.7 [53.0, 67.5]

60.3 [54.4, 67.0]

0.46

Male gender, N (%)

33 (54)

106 (78)

74 (82)

 < 0.001

BMI (kg/m2), median [Q1–Q3]

27.4 [24.5, 31.5]

28.7 [26.6, 31.3]

28.3 [26.3, 31.4]

0.15

Smoking Historya, N (%)

   

0.09

No

40 (85)

76 (64)

47 (64)

 

Active-prior

7 (11)

43 (32)

26 (29)

 

Comorbidities

 Cardiovascular diseases, N (%)

10 (16)

31 (23)

24 (27)

0.32

 Hypertension, N (%)

19 (31)

39 (29)

24 (27)

0.82

 Cerebrovascular diseases, N (%)

1 (2)

3 (2)

1 (1)

1.00

 Asthma, N (%)

8 (13)

4 (3)

4 (4)

0.02

 OSAS, N (%)

2 (3)

3 (2)

1 (1)

0.76

 Chronic kidney diseases, N (%)

4 (7)

2 (1)

3 (3)

0.12

 Liver diseases, N (%)

1 (2)

3 (2)

0 (0)

0.43

 Diabetes, N (%)

10 (16)

18 (13)

13 (14)

0.84

 Prior cancer, N (%)

5 (8)

2 (1)

5 (6)

0.05

No. of comorbidities, N (%)

   

-

 0

20 (33)

64 (47)

36 (40)

 

 1

26 (43)

42 (31)

34 (38)

 

 2

9 (15)

23 (17)

16 (18)

 

 ≥ 3

6 (10)

7 (5)

4 (4)

 

Treatments associated with COVID-19

 Systemic steroidb, N (%)

15 (30)

62 (56)

44 (59)

0.002

 Prophylactic heparinb, N (%)

15 (30)

53 (48)

41 (55)

0.02

 Tocilizumabb, N (%)

3 (6)

17 (15)

17 (23)

0.04

 Remdesivirc, N (%)

1 (2)

2 (2)

11 (15)

0.001

 Mucolyticsc, N (%)

10 (20)

32 (29)

35 (47)

0.004

 Hyperimmune Plasmac, N (%)

0 (0)

1 (1)

1 (1)

1.000

 Lopinavir/ritonavirc, N (%)

19 (38)

73 (66)

36 (49)

0.002

 Hydroxychlorokined, N (%)

39 (78)

95 (87)

58 (79)

0.23

  1. BMI body mass index, CPAP continuous positive airway pressure, IMV invasive mechanical ventilation, Q1–Q3 first-third quartile, OSAS obstructive sleep apnea syndrome
  2. a48 missing
  3. b52 missing
  4. c53 missing
  5. d55 missing